Kimberly-Clark To Acquire Tylenol Maker Kenvue In Giant $40 Billion Merger

Source: Zerohedge
Published: 2025-11-03
Author: Tyler Durden
Post Date: 2025-11-03 08:54:14 by Esso
Views: 39

Consumer products company Kimberly-Clark Corporation announced it will acquire Tylenol maker Kenvue in a cash-and-stock transaction valued at nearly $49 billion, marking one of the largest consumer health mergers in history. 

Kimberly-Clark revealed in a press release that the deal values Kenvue at 14.3x its latest twelve months (LTM) adjusted EBITDA. In return, Kenvue shareholders will receive $3.50 in cash and .14625 Kimberly-Clark shares per Kenvue share, for a total of about $ 21.01 per share. The deal is valued at $48.7 billion. 

The deal is expected to close in 2H 2026. Upon completion, Kimberly-Clark shareholders will own 54% of the combined company, while Kenvue shareholders will own 46%. Both boards have unanimously approved the acquisition. JPMorgan Chase is providing committed financing for the deal. 

The merger unites two mega consumer-product giants, creating a global health and wellness powerhouse with top brands, including Kleenex, Huggies, Tylenol, Neutrogena, Listerine, and Band-Aid, that reach consumers worldwide. 

Here's the justification for the merger:

Combines Kimberly-Clark's commercial execution and digital marketing capabilities with Kenvue's science-backed innovation and healthcare professional networks.

Expands global footprint across key growth categories in personal care and health.

Enhanced R&D and quality investments to accelerate product innovation and address evolving consumer health needs.

Kimberly-Clark CEO Mike Hsu will continue leading the merged company, supported by senior executives from both firms.

Based on Kimberly-Clark's current projections, the merger would generate 2025 annual net revenues of about $32 billion and adjusted EBITDA of about $7 billion. 

All sounds great, but this comes at a time when Tylenol faces political scrutiny via the Trump administration, warning mothers to avoid giving their newborns acetaminophen.

Related:

"Don't Take It": Trump Warns Pregnant Women To Avoid Tylenol Over Autism Concerns

Tylenol Manufacturer Resists Proposed Label Changes

In markets, Kimberly-Clark shares tumbled 15%, while Kenvue shares jumped 20%.

The question now is whether government regulators will approve the deal, especially given President Trump's recent comments surrounding Tylenol.

Post Comment   Private Reply

#1: Esso    To: Esso (#0)

Maybe K-C could acquire Cracker Barrel and Chipotle with Dylan Mulvaney as their spokesman.

Esso posted on 2025-11-03 08:56:37   Reply   Private Reply

#2: Esso    To: All (#1)

Kimberly-Clark Suffers Biggest Loss Since 'Black Monday' After Unveiling $40 Billion Merger With Tylenol-Maker Kenvue
Kimberly-Clark shares remain down around 14.5% in late-afternoon trading.  If the losses hold into the close, it would mark the company's steepest one-day drop since October 16, 1987, or just days before the Black Monday crash on October 19, 1987. Earlier, the Kleenex maker unveiled plans to acquire Tylenol producer Kenvue in a $48.7 billion cash-and-stock deal. The announcement sent Kenvue soaring, up 20%. 

https://www.zerohedge.com/markets/kimberly-clark-acquire-tylenolmaker-kenvue-giant-40-billion-merger

Esso posted on 2025-11-03 14:36:31   Reply   Private Reply